Clinical consumption of opioid analgesics in China: a retrospective analysis of the national and regional data 2006-2016.
This study analyzed the clinical consumption, estimated the needs of pain treatment, and evaluated the adequacy of opioid analgesics consumption in mainland China and its seven regions. A retrospective analysis of the national and regional consumption of opioid analgesics in mainland China during 2006-2016 was conducted. The Adequacy of Consumption Measure was used to gauge the overall adequacy of opioid analgesics consumption in morphine equivalents for the treatment of moderate to severe pain in mainland China and compared with international data. Annual per capita consumption was adopted to measure the clinical consumption of opioid analgesics in morphine equivalents at a national level and across seven regions of mainland China. Needs of morphine for cancer pain treatment in mainland China and in its seven regions were estimated and compared with the clinical consumption of opioid analgesics in morphine equivalents. The Adequacy of Consumption Measure of mainland China ranged from 0.0041 to 0.0088 during 2006-2016, which was less than 1% of that in the reference countries. The poor North East region had only 10.85% of the cancer pain morphine needs fulfilled. The highest fulfillment rate was 36.02% in rich Southern China, which was 25.9% at the national level. The clinical consumption of opioid analgesics for the treatment of moderate to severe pain in mainland China was far below the international level. The Annual per capita of clinical consumption was lower, and the adequacy of cancer pain treatment was poorer in less developed areas. All these findings call for actions to strengthen pain management.